ASTELLAS PHARMA A/S: Financial statements 2017
CVR: 10888638
Source: annual report 2017, Danish Business Authority
01/04/2016 – 31/03/2017
ASTELLAS PHARMA A/S (CVR 10888638) has filed annual accounts for 2017. In 2017, the company reported revenue of EUR 144,927,000 and a net result of EUR 12,189,000 compared with EUR 6,656,000 the year before. That is a decrease of 7.1% compared with the year before. The profit margin was 8.4%. Equity in the 2017 report amounted to EUR 51,540,000. The solvency ratio was 62.7%. The company had 117 employees in the financial year.
- Revenue
- EUR 144,927,000
- Gross Profit
- EUR 17,904,000
- Profit/Loss
- EUR 12,189,000
- Equity
- EUR 51,540,000
- Total Assets
- EUR 82,219,000
- Employees
- 117
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2017 | 144.9 mio. EUR | 17.9 mio. EUR | 12.2 mio. EUR | 51.5 mio. EUR | 117 |
| 2016 | 156 mio. EUR | - | 6.7 mio. EUR | 45.4 mio. EUR | 118 |
| 2015 | 121.9 mio. EUR | 25.8 mio. EUR | 5.3 mio. EUR | 38.7 mio. EUR | 116 |
| 2014 | 97 mio. EUR | 26.5 mio. EUR | 7 mio. EUR | 38.4 mio. EUR | 112 |
| 2013 | 93 mio. EUR | 23.6 mio. EUR | 5.7 mio. EUR | 34.4 mio. EUR | 90 |
Official annual report
Keep an eye on ASTELLAS PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringAbout ASTELLAS PHARMA A/S
ASTELLAS PHARMA A/S is a Danish company of the type Aktieselskab based in København S, founded in 1987. The company is registered under the industry Engroshandel med medicinalvarer og sygeplejeartikler. The company was previously named YAMANOUCHI PHARMA A/S and BROCADES PHARMA A/S. The management consists of Mark Andree Dekker. The board consists of Damla Ebru Atilgan (chair), Anne Nymand, Giuseppe Maduri and Mark Andree Dekker. The company is owned by Astellas Pharma Europe LTD.. The company has 67 employees (2026). In 2026, the company reported revenue of EUR 197,863,000 and a net result of EUR 5,229,000 compared with EUR 5,705,000 the year before. Equity in the 2026 report amounted to EUR 20,071,000.